Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, AND 2020.(23-09-2025)

Dapotopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: Results from the PHASE II  TROPION-Lung05 Study.(03-06-2025)

First-Line Mobocertinib versus Platinum-based Chemotherapy in patients with EGFR EXON 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the PHASE III EXCLAIM-2 TRIAL.(06-05-2025)

Phase II Efficacy and Safety of 80 mg Osimertinib in patients with Letomeningeal Metastase Associated with Epidermal Growth Fact0r Receptor mutation-positive Non-Small Cell Lung Cancer (BLOSSOM).(25-03-2025)

Osimertinib after Chemoradiotherapy in stage III EGFR-MUTATED NSCLC.(18-03-2025)

Cemiplimab plus Chemotherapy versus Chemotherapy alone in Non-Small Cell Lung Cancer with PD-L1 ≥ 1%: a subgroup analysis from the EMPOWER-LUNG 3 PART 2 trial.(04-02-2025)

Lorlatinib versus Crizotinib in patients with Advanced Alk-positive  Non-Small Cell Lung Cancer: 5-year outcomes from the phase III crown study.(02/07/2024)

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.(25/06/2024)

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. (04/06/2024)

Impact of Immune Checkpoint Inhibitors on Atherosclerosis Progression in Patients with Lung Cancer. (21/11/2023)

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial